

Date: 12-11-01

Date of O.A.:

via Certificate of Matri-

20. # \_\_\_\_\_ issued

SECRET: SECRET Art Unit: SECRET

Batch: \_\_\_\_\_ Assy: \_\_\_\_\_

Applicant: John A. Smith

Title: Book of Numbers

Re-Exam Control # \_\_\_\_\_

VERIFIED BY: [Signature] Quality Control: [Signature]

2. Amendment is \_\_\_\_\_

Mo. Exp. Time is exp. ☒ Change of Address

☐ Request for Drawing Changes ☐ Small Entity Statement

Page 5

Check for Arima, \_\_\_\_\_

~~CONFIDENTIAL~~

Information Disclosure Case No. 10-1449 is duplicate with \_\_\_\_\_ reference(s)

2. \_\_\_\_\_

Nixon Peabody LLP

APR 21 1968  
176/60901  
95

PATENT  
Docket No.: 176/60901 (6-11402-968)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Shohei Koide	)	Examiner:
		)	Unknown
Serial No. :	10/006,760	)	
		)	Art Unit:
Confrm No. :	Unknown	)	Unknown
		)	
Filed :	November 19, 2001	)	
		)	
For :	METHOD OF IDENTIFYING POLYPEPTIDE	)	
	MONOBODIES WHICH BIND TO TARGET	)	
	PROTEINS AND USE THEREOF	)	

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:


Pursuant to 37 CFR §§ 1.97-1.98, applicant hereby brings to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO-1449 form.

Respectfully submitted,

Date: December 18, 2001

  
Edwin V. Merkel  
Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603  
Telephone: (716) 263-1128  
Facsimile: (716) 263-1600

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.	
Date	<u>12/18/01</u>  Wendy L. Harold

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449)	APP. DOCKET NO.		SERIAL NO.
	176/00011 (6-11402-868)		10/086,768
	APPLICANT		
	Shohei Koide		
FILING DATE		GROUP ART UNIT	
November 19, 1993		To Be Assigned	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPRO- PRIATE
1	WO 93/06915	12/17/1993	WFO			

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	2	Koide et al., "The Fibronectin Type III Domain as a Scaffold for Novel Binding Proteins," <i>J. Mol. Biol.</i> 284:1143-1153 (1999)
	3	Koide et al., "Stabilization of a Fibronectin Type III Domain by the Removal of Unfavorable Electrostatic Interactions on the Protein Surface," <i>Biochemistry</i> 40:10326-10333 (2001)
	4	Koide et al., "Probing Protein Conformational Changes Inside the Cell Using Designer Binding Proteins: Application to Protein Receptors," <i>Protein Science</i> 10(2):142 (2001)
	5	Richardson et al., "Phenotypic Knockout of the High-Affinity Human Interleukin 2 Receptor by Intracellular Single-Chain Antibodies Against the $\alpha$ Subunit of the Receptor," <i>Proc. Natl. Acad. Sci. USA</i> 92:3137-3141 (1995)
	6	Abeshi et al., "Green Fluorescent Protein as a Scaffold for Intracellular Presentation of Peptides," <i>Nucleic Acid Research</i> 26(2):623-635 (1998)
	7	Dente et al., "Small Antibody-Like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," <i>Proc. Natl. Acad. Sci. USA</i> 96:1878-1903 (1999)
	8	Paige et al., "Estrogen Receptor (ER) Modulators Elicited Induce Distinct Conformational Changes in ER $\alpha$ and ER $\beta$ ," <i>Proc. Natl. Acad. Sci. USA</i> 96:3999-4004 (1999)
	9	Smith, "Patch Engineering: a General Approach for Creating Proteins That have New Binding Activities," <i>TIBS</i> 23:457-460 (1998)
	10	Taddei et al., "In Vivo Selection of Single-Chain Antibodies Using a Yeast Two-Hybrid System," <i>Journal of Immunological Methods</i> 238:161-172 (2000)
EXAMINER:		DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 9. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use several sheets if necessary)  (PTO-1449)	APP. DOCKET NO.  176/00981 (6-11401-901)		SERIAL NO.  10086,760
	APPLICANT  Shahel Kaido		
	FILED DATE  November 30, 2001	GROUP ART UNIT  To Be Assigned	

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILED DATE IF APPRO- PRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION IF APPRO- PRIATE

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

11	Norris et al., "Peptide Antagonists of the Human Estrogen Receptor," <i>Science</i> 280:744-746 (1998).
12	Chen et al., "Transcriptional Activation of the Human Estrogen Receptor by DDT Isomers and Metabolites in Yeast and MCF-7 Cells," <i>Biochemical Pharmacology</i> 59:1161-1172 (1997).
13	Colas et al., "The Impact of Two-Hybrid and Related Methods on Biotechnology," <i>TECHON</i> 16:355-363 (1999).
14	Fields et al., "A Novel Genetic System to Detect Protein-Protein Interactions," <i>Nature</i> 340:745-746 (1993).
15	Ikeda-Fukuda et al., "Applications of Interaction Traps Two-Hybrid Systems to Biotechnology Research," <i>Biotechnology</i> 8:482-486 (1994).
16	Cera et al., "Systematic and Large-Scale Two-Hybrid Screens," <i>Current Opinion in Microbiology</i> 3:303-308 (2000).
EXAMINER	DATE CONSIDERED
EXAMPLE: Initial if citation considered, whether or not citation is in conformance with MPEP 6 02; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	